GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » 3-Year EBITDA Growth Rate

Roquefort Therapeutics (LSE:ROQ) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics 3-Year EBITDA Growth Rate?

Roquefort Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was £-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Roquefort Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Roquefort Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roquefort Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's 3-Year EBITDA Growth Rate falls into.



Roquefort Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Roquefort Therapeutics  (LSE:ROQ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Roquefort Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics (LSE:ROQ) Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines